VNRX - VolitionRx Limited

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
0
0
0
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
0
Operating Expenses
Research Development
10,751
10,907
8,906
6,838
6,102
Selling General and Administrative
6,013
6,954
6,125
5,429
3,904
Total Operating Expenses
16,804
17,898
15,046
11,905
9,859
Operating Income or Loss
-16,804
-17,898
-15,046
-11,905
-9,859
Interest Expense
125
111
73
-
-
Total Other Income/Expenses Net
-
-
350
361
324
Income Before Tax
-17,125
-18,009
-14,769
-11,905
-9,535
Income Tax Expense
-
-
0
0
-5
Income from Continuing Operations
-17,125
-18,009
-14,769
-11,905
-9,530
Net Income
-17,125
-18,009
-14,769
-11,905
-9,530
Net Income available to common shareholders
-17,125
-18,009
-14,769
-11,905
-9,530
Reported EPS
Basic
-
-0.57
-0.56
-0.52
-0.54
Diluted
-
-0.57
-0.56
-0.52
-0.54
Weighted average shares outstanding
Basic
-
31,389
26,390
23,049
17,732
Diluted
-
31,389
26,390
23,049
17,732
EBITDA
-
-17,261
-14,168
-11,596
-9,623